English
Français
Paris (France), on June 20, 2025.
Dear shareholders,
We, Mrs. Dominique Costantini, Mr. Emile Loria and Mr. Alexis Peyroles, hereby inform the shareholders of OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) of recent developments regarding the holding of the Company’s combined general meeting initially convened for June 25, 2025, and adjourned by the Company’s Board of directors on June 11, 2025[1].
We intend to challenge the order issued by the President of the Nantes Commercial Court on June 10, 2025 (the “Order”), pursuant to which the period allowed for the Company to hold its annual general meeting, i.e. until June 30, 2025, as provided for in article L. 225-100 of the French Commercial Code, was extended to September 30, 2025.
To this end, on June 18, 2025, we filed a requête aux fins d’être autorisés à assigner en référé à heure indiquée before the President of the Nantes Commercial Court.
Pursuant to an order issued on the same day, the President of the Nantes Commercial Court granted our request and set the hearing (the “Hearing”) for Tuesday, June 24, 2025, during which the Company will be able to develop its arguments.
During the Hearing, we will ask the President of the Nantes Commercial Court (i) primarily, to cancel (rétracter) the Order and (ii) in the alternative, to amend the Order so as to authorize the extension of the deadline for the Company to hold its annual general meeting until July 31, 2025 only.
We hope that the postponed general meeting can be held as soon as possible so as to enable the shareholders to cast their votes, and we reaffirm our determination to defend transparency, fairness and shareholder democracy, in compliance with the legal and regulatory framework.
We will communicate in due course on the progress of this procedure through our dedicated website https://ose-ag2025.com/.
Mrs. Dominique Costantini
Mr. Emile Loria
Mr. Alexis Peyroles
[1] Press release of the Company dated June 11, 2025.